Researchers Discover Key Molecule to Improve Cystic Fibrosis Treatment

Emmanuelle Brochiero is a researcher at CRCHUM and a professor at the University of Montreal who explained the value of the study, "adding molecules called quorum-sensing inhibitors to current drugs not only reduces production of harmful residues but also restores the efficacy of existing treatments on the cells of cystic fibrosis patients. Patients with cystic fibrosis present genetic defects that cause the abnormal production of a protein called CFTR in cells and an excess of mucus in organs. Current drugs act to correct the defect in the CFTR protein. In a sterile in vitro environment, Kalydeco and Orkambi treatments work well. But in real life, the lungs of sick patients are colonized by bacteria, Pseudomonas aeruginosa in particular. Much evidence has indicated that bacteria could interfere with the treatment. Thanks to this study, we have been able to determine which substances released by the bacteria could reduce the efficacy of the treatments."

This breakthrough is absolutely crucial, as many experience the frustration of receiving a drug or treatment that works miracles for some, but not at all for others. The quorum-sensing inhibitors may be able to ensure the effectiveness of treatment for far more patients now.